References and Notes
1a
Turck A.
Plé N.
Mongin F.
Queguiner G.
Tetrahedron
2001,
57:
4489
1b
Turck A.
Plé N.
Queguiner G.
Heterocycles
1994,
37:
2149
2a
Parkanyi C.
Cho NS.
Yoo GS.
J. Organometal. Chem.
1988,
342:
1
2b
Friseen AE.
Marcelis ATM.
Buurman CA.
Pollmann CAM.
Van der Plas HC.
Tetrahedron
1989,
45:
5611
2c
Langley BW.
J. Am. Chem. Soc.
1956,
78:
2136
2d
Ulbricht BW.
J. Am. Chem. Soc.
1959,
6:
225
2e
Arai I.
Daves GD.
J. Chem. Soc., Chem. Commun.
1976,
69
2f
Strekowski L.
Roczniki Chemii
1975,
49:
1643
2g
Brown D.
Ogden RC.
J. Chem. Soc., Perkin Trans. 1
1981,
723
2h
Strekowski L.
Watson R.
J. Org. Chem.
1986,
51:
3226
2i
Yokoyama M.
Ikene T.
Ochiai Y.
Momotake A.
Yamaguchi K.
Togo H.
J. Chem. Soc., Perkin Trans. 1
1998,
2185
2j
Yokoyama M.
Ikenogami T.
Togo H.
J. Chem. Soc., Perkin Trans. 1
2000,
2067
2k
Hanessian S.
Machaalani R.
Tetrahedron Lett.
2003,
44:
8321
2l
von Angerer S. In Science of Synthesis
Vol. 16:
Black DStC.
Thieme;
Stuttgart:
2004.
p.379
2m
Rajkumar TV.
Binkley SB.
J. Med. Chem.
1963,
6:
550
3a
Hirschberg A.
Peterkofsky A.
Spoerri PE.
J. Heterocycl. Chem.
1965,
2:
209
3b
Hertz HS.
Kabacinski FF.
Spoerri PE.
J. Heterocycl. Chem.
1969,
6:
239
3c
Baker R.
Street LJ.
Reeve AJ.
Saunders J.
J. Chem. Soc., Chem. Commun.
1991,
760
3d
Sato N. In Science of Synthesis
Vol. 16:
Black DStC.
Thieme;
Stuttgart:
2004.
p.751
3e Stevenson, T. M.; Crouse, B. A.; Thieu, T. V.; Gebreysus, C.; Piotrowski, D. L. Abstracts of Papers, 228th National Meeting of the American Chemical Society, Philadelphia, 2004; American Chemical Society: Washington DC, 2004.
3f
Street LJ.
Baker R.
Book T.
Reeve AJ.
Saunders J.
Willson T.
Marwood RS.
Patel S.
Freedman S.
J. Med. Chem.
1992,
35:
295
4a
Plé N.
Turck A.
Couture K.
Tetrahedron
1994,
50:
10299
4b
Toudic F.
Plé N.
Turck A.
Queguiner G.
Tetrahedron
2002,
58:
283
5a
Abarbri M.
Knochel P.
Synlett
1999,
1577
5b
Leprêtre A.
Turck A.
Plé N.
Knochel P.
Queguiner G.
Tetrahedron
1999,
56:
265
5c
Momotake A.
Mito J.
Yamaguchi K.
Togo H.
Yokoyama M.
J. Org. Chem.
1998,
63:
7207
5d
Shimura A.
Momotake A.
Togo H.
Yokoyama M.
Synthesis
1999,
495
5e
Momotake A.
Togo H.
Yokoyama M.
J. Chem. Soc., Perkin Trans. 1
1999,
1193
6a
Dumouchel S.
Mongin F.
Trécourt F.
Queguiner G.
Tetrahedron
2003,
59:
8629
6b
Dumouchel S.
Mongin F.
Trécourt F.
Queguiner G.
Tetrahedron Lett.
2003,
44:
2033
7a
Hirschberg A.
Spoerri PE.
J. Org. Chem.
1961,
26:
1907
7b
Street LJ.
Baker R.
Book T.
Reeve A.
Saunders J.
J. Med. Chem.
1992,
35:
295
7c
Majeed AJ.
Antonsen O.
Benneche T.
Undheim K.
Tetrahedron
1989,
45:
993
8
Procedure 1 for 2-Iodopyrazine and 4-Iodo-2-methyl-sulfanylpyrimide.
A solution of n-BuLi (1.6 M in hexane, 0.66 mmol) was added to a cold (-10 °C) stirred solution of n-butyl-magnesium chloride (0.33 mmol) in THF (5 mL). After 1 h at -10 °C a solution of iododiazine (1 mmol) in THF (2 mL) was added at -30 °C and the mixture was stirred at -10 °C for 2.5 h. The electrophile (1.5 mmol) was then added at
-10 °C; the mixture was stirred at this temperature for 1 h and kept at r.t. for 18 h before addition of H2O (1 mL). The reaction mixture was diluted with EtOAc (50 mL). The organic layer was dried over MgSO4 and evaporated. The crude product was purified by column chromatography on silica gel.
Representative Spectroscopic Data2-(1-Hydroxy-4-methoxyphenylmethyl) Pyrazine (
2)
Prepared according to procedure 1. 1H NMR (CDCl3): δ = 8.50 (s, 1 H, H3), 8.36 (d, 1 H, J = 2.5 Hz, H6), 8.31 (d, 1 H, J = 2.5 Hz, H5), 7.18 (d, 2 H, J = 8.7 Hz, HPh2,6), 6.76 (d, 2 H, J = 8.7 Hz, HPh3,5), 5.71 (s, 1 H, CH), 4.74 (m, 1 H, OH), 3.68 (s, 3 H, OCH3). 13C NMR (CDCl3): δ = 159.4 (CPh4), 157.5 (C2), 143.2-143.0 (C3, C5 and C6), 134.2 (CPh1), 128.2 (CPh2,6), 114.2 (CPh3,5), 73.9 (CH), 55.3 (OCH3). IR (KBr): 3352, 2930, 2840, 1613, 1513, 1469, 1403, 1304, 1249, 1149, 1064, 832, 582 cm-1. Anal. Calcd for C12H12N2O2 (216.24): C, 66.65; H, 5.59; N, 12.96. Found: C, 66.90; H, 5.47; N, 12.91.
2-Methylsulfanyl-4-(1-hydroxy-4-methoxyphenyl-methyl) Pyrimidine (
7)
Prepared according to procedure 1. 1H NMR (CDCl3): δ = 8.33 (d, 1 H, J = 5.3 Hz, H6), 7.21 (d, 2 H, J = 8.7 Hz, HPh2,6), 6.81 (d, 2 H, J = 8.7 Hz, HPh3,5), 6.72 (d, 1 H, J = 5.1 Hz, H5), 5.53 (d, 1 H, J = 3.8 Hz, CH), 4.51 (m, 1 H, OH), 3.73 (s, 3 H, OCH3), 2.53 (s, 3 H, SCH3). 13C NMR (CDCl3): δ = 172.2 (C2 and C4), 159.8 (CPh4), 157.3 (C6), 133.6 (CPh1), 129.6 (CPh2,6), 114.5 (CPh3,5), 113.5 (C5), 74.3 (CH), 55.4 (OCH3), 14.3 (SCH3). IR (KBr): 3369, 2929, 2836, 1565, 1513, 1349, 1249, 1174, 1032, 832 cm-1. Anal. Calcd for C13H14N2O2S (262.33): C, 59.52; H, 5.38; N, 10.68. Found: C, 59.34; H, 5.42; N, 10.75.
9
Procedure 2 for 2-Iodo-6-phenylpyridazine.
A solution of n-BuLi (1.6 M in hexane, 0.66 mmol) was added to a cold (-10 °C) stirred solution of n-butyl-magnesium chloride (0.33 mmol) in THF (5 mL). After 1 h at -10 °C, The solution was added in a solution of 2-iodo-6-phenylpyridazine (1 mmol) in THF (2 mL) at -30 °C and the mixture was stirred at -10 °C for 2.5 h. The electrophile (1.5 mmol) was then added at -10 °C; the mixture was stirred at this temperature for 1 h, then brought to, and kept at, 35 °C for 18 h before addition of H2O (1 mL). The reaction mixture was diluted with EtOAc (50 mL). The organic layer was dried over MgSO4 and evaporated. The crude product was purified by column chromatography on silica gel.
Representative Spectroscopic Data3-(1-Hydroxy-4′-methoxyphenylmethyl)-6-phenyl Pyridazine (
12)
Prepared according to procedure 2. Mp 140 °C. 1H NMR (CDCl3): δ = 8.05 (m, 2 H, HPh2,6), 7.77 (d, 1 H, J = 8.9 Hz, H5), 7.40 (m, 6 H, H4, HPh
′
2,6, HPh3,4,5), 6.88 (d, 2 H, J = 8.7 Hz, HPh
′
3,5), 6.02 (s, 1 H, CH), 5.02 (m, 1 H, OH), 3.78 (s, 3 H, OCH3). 13C NMR (CDCl3): δ = 161.7 (CPh
′
4), 159.6 (C3 and C6), 135.9 (CPh1), 134.1 (CPh
′
1), 130.3-124.9 (C4, C5, CPh2,6, CPh
′
2,6, CPh4, CPh3,5), 114.3 (CPh
′
3,5), 74.4 (CH), 55.4 (OCH3). IR (KBr): 3135, 2999, 2933, 2838, 1611, 1514, 1433, 1251, 1171, 1064, 813, 692 cm-1. Anal. Calcd for C18H16N2O2 (292.34): C, 73.96; H, 5.52; N, 9.58. Found: C, 73.68; H, 5.48; N, 9.32.